Vyvanse shortages return

Less than two months after the TGA declared shortages of Vyvanse to be “resolved” the regulator is now reporting the medication is once again in short supply  The Therapeutic Goods Administration (TGA) is reporting that Vyvanse (lisdexamfetamine dimesilate) 20mg capsules are once again in short supply.   Takeda Pharmaceuticals Australia notified the regulator of the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Guild secures trial funding support
Next Tasmanian pharmacist OCP resupply initiative commences 1 July 2024